Poolbeg Pharma to test the treatment in NHS hospitals and says it is also developing a GLP-1 weight loss pill

A London-based startup is about to trial a drug at six NHS hospitals that could stop people on cancer immunotherapy getting a life-threatening side-effect.

Poolbeg Pharma said its oral drug POLB 001 could make treatment for blood cancer safer by preventing cytokine release syndrome (CRS), when the immune system goes into overdrive and attacks the body, leading to organ damage.

Exclusive: Cancer charity says dispelling falsehoods gleaned from social media is now routine task for clinicians

Social media misinformation about the use of dietary supplements such as turmeric, St John’s wort and magnesium is now so common that dispelling online claims has become a routine part of NHS clinicians work.

Two out of five frontline health workers say they encounter patients who raise inaccurate or misleading information about supplements at least once a week.